Navigation Links
The Complexities, Cost of Midwest Biotech Drug Development

CHICAGO In trying to explain the complexities of the biotech industry to investors, academics and start-up biotech companies, most people now understand that it is a long, painstaking and expensive process. What they don't understand is why.

A brief primer in the drug discovery and development process shows us the following pathway:



Logical questions to the above inc......

Full article >>> ese type of diseases by granting orphan drug designation. This designation provides a company with both fast-track review as well as seven years market exclusivity from the time the drug is actually approved by the FDA (independent of the drugs patent status).

Another situation with the FDA exists for drugs for life-threatening disea......

Full article >>> nt to 80 percent of the cost and about 60 percent of the time to develop a drug is in the clinical phase of development (testing in humans), it is critical to ask this question up front before even starting clinical trials.

It has been said that it costs up to $800 to $900 million for Big Pharma to develop a successful drug. That is a higher amount than you are citing. Why?
......

Full article >>> y.

Happy Thanksgiving! See you next week!

......

Full article >>>
'"/>

Source:wistechnology.com By Michael Rosen 11/24/03


Related biology technology :

1. Midwest life science stocks kept sizzling in Q2
2. Midwest life science stocks sizzle in a tepid first quarter
3. A Midwest passage to India, Part II
4. Midwest offers non-stop flight to North Carolina research park
5. A Midwest life-science odyssey comes full circle
6. Midwest hotter for healthcare investments
7. A Midwest small-cap, life-science surprise package
8. 2006: A mixed blessing for Midwest life science companies
9. Midwest gaining stature in nanotech research
10. Midwest colleges strong contenders for NIH funds
11. Japan on the rebound: Implications for Midwest
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)...  Sequenom, Inc. (NASDAQ: SQNM ), a ... the development of innovative products and services, announced today ... States denied its petition to review decisions ... U.S. Patent No. 6,258,540 (",540 Patent") are not patent ... Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, ... faculty of the University of North Carolina Kenan-Flagler Business School effective ... at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
Breaking Biology Technology:
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):